sk&f 86002 has been researched along with Acquired Immune Deficiency Syndrome in 1 studies
6-(4-fluorophenyl)-2,3-dihydro-5-(4-pyridinyl)imidazo(2,1-b)thiazole: inhibits p38 MAP kinase
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bender Ignacio, RA | 1 |
| Lee, JY | 1 |
| Rudek, MA | 1 |
| Dittmer, DP | 1 |
| Ambinder, RF | 1 |
| Krown, SE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I/II Trial of PTC299 in Patients With HIV-Related Kaposi's Sarcoma[NCT00686842] | Phase 1/Phase 2 | 17 participants (Actual) | Interventional | 2008-09-30 | Terminated (stopped due to Drug supply unavailable.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Patients who experienced an adverse event of grade 3 or greater (NCT00686842)
Timeframe: All study visits
| Intervention | participants (Number) |
|---|---|
| VEGF Inhibitor PTC299 | 7 |
1 trial available for sk&f 86002 and Acquired Immune Deficiency Syndrome
| Article | Year |
|---|---|
Brief Report: A Phase 1b/Pharmacokinetic Trial of PTC299, a Novel PostTranscriptional VEGF Inhibitor, for AIDS-Related Kaposi's Sarcoma: AIDS Malignancy Consortium Trial 059.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; DNA, Viral; Enzyme | 2016 |